[go: up one dir, main page]

WO2005009989A8 - Nicotinamide derivatives useful as pde4 inhibitors - Google Patents

Nicotinamide derivatives useful as pde4 inhibitors

Info

Publication number
WO2005009989A8
WO2005009989A8 PCT/IB2004/002376 IB2004002376W WO2005009989A8 WO 2005009989 A8 WO2005009989 A8 WO 2005009989A8 IB 2004002376 W IB2004002376 W IB 2004002376W WO 2005009989 A8 WO2005009989 A8 WO 2005009989A8
Authority
WO
WIPO (PCT)
Prior art keywords
nicotinamide derivatives
pde4 inhibitors
derivatives useful
preparation
nicotinamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2004/002376
Other languages
French (fr)
Other versions
WO2005009989A1 (en
Inventor
Simon Bailey
Christopher Gordon Barber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Ltd Great Britain
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Ltd Great Britain, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Priority to JP2006521685A priority Critical patent/JP2006528659A/en
Priority to BRPI0412253-4A priority patent/BRPI0412253A/en
Priority to MXPA06000989A priority patent/MXPA06000989A/en
Priority to CA002533663A priority patent/CA2533663A1/en
Priority to EP04744035A priority patent/EP1651635A1/en
Publication of WO2005009989A1 publication Critical patent/WO2005009989A1/en
Anticipated expiration legal-status Critical
Publication of WO2005009989A8 publication Critical patent/WO2005009989A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to nicotinamide derivatives of general formula (I) in which X, Y, n, Z, L and R have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivates.
PCT/IB2004/002376 2003-07-25 2004-07-13 Nicotinamide derivatives useful as pde4 inhibitors Ceased WO2005009989A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006521685A JP2006528659A (en) 2003-07-25 2004-07-13 Nicotinamide derivatives useful as PDE4 inhibitors
BRPI0412253-4A BRPI0412253A (en) 2003-07-25 2004-07-13 nicotinamide derivatives useful as pde4 inhibitors
MXPA06000989A MXPA06000989A (en) 2003-07-25 2004-07-13 Nicotinamide derivatives useful as pde4 inhibitors.
CA002533663A CA2533663A1 (en) 2003-07-25 2004-07-13 Nicotinamide derivatives useful as pde4 inhibitors
EP04744035A EP1651635A1 (en) 2003-07-25 2004-07-13 Nicotinamide derivatives useful as pde4 inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0317472.9 2003-07-25
GBGB0317472.9A GB0317472D0 (en) 2003-07-25 2003-07-25 Nicotinamide derivatives useful as PDE4 inhibitors

Publications (2)

Publication Number Publication Date
WO2005009989A1 WO2005009989A1 (en) 2005-02-03
WO2005009989A8 true WO2005009989A8 (en) 2006-03-02

Family

ID=27772706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/002376 Ceased WO2005009989A1 (en) 2003-07-25 2004-07-13 Nicotinamide derivatives useful as pde4 inhibitors

Country Status (7)

Country Link
EP (1) EP1651635A1 (en)
JP (1) JP2006528659A (en)
BR (1) BRPI0412253A (en)
CA (1) CA2533663A1 (en)
GB (1) GB0317472D0 (en)
MX (1) MXPA06000989A (en)
WO (1) WO2005009989A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060272A1 (en) 2004-05-24 2006-05-22 Glaxo Group Ltd (2R, 3R, 4S, 5R, 2'R, 3'R, 4'S, 5'S) -2.2 '- {TRANS-1,4-CYCLOHEXANODIYLBIS- [IMINO (2 - {[2- (1-METHYL- 1H-IMIDAZOL-4-IL) ETHYL] AMINO} -9H-PURIN-6,9-DIYL)]} BIS [5- (2-ETHYL-2H-TETRAZOLE-5-IL) TETRAHYDRO-3,4-FURANODIOL] AS AN A2A AGONIST
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US8420647B2 (en) 2010-01-21 2013-04-16 Hoffmann-La Roche Inc. 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
EP3053911B1 (en) * 2013-09-30 2020-01-22 The University of Tokyo Adiponectin receptor-activating compound
EP4149929A1 (en) * 2020-05-12 2023-03-22 Bayer Aktiengesellschaft Triazine and pyrimidine (thio)amides as fungicidal compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861891A (en) * 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
TW429148B (en) * 1995-10-27 2001-04-11 Pfizer Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
US6380218B1 (en) * 1997-04-04 2002-04-30 Pfizer Inc Nicotinamide derivatives
GB9715584D0 (en) * 1997-07-23 1997-10-01 Eisai Co Ltd Compounds
DE19854081A1 (en) * 1998-11-24 2000-05-25 Bayer Ag New 2-phenoxy-N-pyrazolyl-nicotinamide derivatives, useful as pre- or post-emergence, total or selective herbicides
ES2292988T3 (en) * 2002-02-11 2008-03-16 Pfizer Inc. USEFUL NICOTINAMIDE DERIVATIVES AS PDE INHIBITORS 4.

Also Published As

Publication number Publication date
BRPI0412253A (en) 2006-09-19
GB0317472D0 (en) 2003-08-27
WO2005009989A1 (en) 2005-02-03
EP1651635A1 (en) 2006-05-03
JP2006528659A (en) 2006-12-21
CA2533663A1 (en) 2005-02-03
MXPA06000989A (en) 2006-04-27

Similar Documents

Publication Publication Date Title
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2004074244A3 (en) Pyrimidine compounds
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
PT1625126E (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors
WO2003074500A3 (en) N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2005021536A3 (en) Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2003095455A3 (en) Substituted pyrazolopyrimidines
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2004018451A8 (en) Pyridazinone-derivatives as pde4 inhibitors
WO2005007085A3 (en) Pyrazolo pyrimidine derivatives and methods of use thereof
TW200628463A (en) Heteroaryl compounds
WO2008013838A3 (en) Pyridizinone derivatives
WO2005058843A8 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
WO2005005389A3 (en) Malonamide derivatives
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
WO2006052568A3 (en) Tgf-beta inhibitors
CY1106343T1 (en) NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2005009965A8 (en) Nicotinamide derivatives useful as pde4 inhibitors
WO2006024640A3 (en) Triazolophthalazines
WO2004110990A3 (en) Imidazothiazoles and imidazoxazole derivatives as inhibitors of p38
WO2006072612A3 (en) Triazolophthalazines as pde2- inhibitors
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
MXPA06000987A (en) Nicotinamide derivatives useful as pde4 inhibitors.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2533663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/000989

Country of ref document: MX

Ref document number: 2006521685

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004744035

Country of ref document: EP

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 05/2005 UNDER (72, 75) THE ADDRESS OF "BAILEY, SIMON" SHOULD READ "PFIZER GLOBAL RESEARCH AND DEVELOPMENT, PATENT DEPARTMENT, AGOURON/PFIZER LA JOLLA, 10777 SCIENCE CENTER DRIVE, SAN DIEGO, CA 92121 (US)"; UNDER (72, 75) THE NATIONALITY AND RESIDENCE OF "BAILEY, SIMON" SHOULD READ "[GB/US]"

WWP Wipo information: published in national office

Ref document number: 2004744035

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0412253

Country of ref document: BR

WWW Wipo information: withdrawn in national office

Ref document number: 2004744035

Country of ref document: EP